TDK Corporation's subsidiary, TDK Ventures, has invested in green hydrogen company Verdagy to accelerate hydrogen electrolysis technology commercialization. This investment, part of TDK's commitment to clean technology, follows Verdagy's recent spin-off from Chemetry and aims to scale production of green hydrogen, crucial for decarbonizing industries. The $25M funding round, involving multiple investors, will support Verdagy in demonstrating its first commercial electrolyzer stack. Verdagy's innovative approach combines alkaline and proton-exchange electrolysis, promising low operational costs and compliance with U.S. Department of Energy targets.
TDK Corporation announced that its subsidiary, TDK Ventures, has invested in the biotech company Mekonos, which specializes in integrated molecular delivery chips for cell and gene therapies. This investment aligns with TDK's commitment to MEMS and BioMEMS innovations aimed at scaling healthcare solutions. The global market for cell and gene therapy is projected to reach $70.5 billion by 2026, growing at a CAGR of 52%. Mekonos has raised $25 million in a Series A round, with TDK joining other notable investors to advance novel therapies.